A Randomized, Double-Blind, Placebo-Controlled, Pilot Study To Evaluate The Efficacy And Safety Of Venlafaxine Extended-Release In Depressed And Anxious Patients With Multiple, Unexplained Somatic Symptoms

Wyeth is now a wholly owned subsidiary of Pfizer0 sites210 target enrollmentAugust 2004

ConditionsAnxiety Disorders Depression

DrugsVenlafaxine XR

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Anxiety Disorders
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment: 210
Primary Endpoint: The primary endpoint is the change from baseline to Week 12 in the PHQ-15 total score.
Status: Completed
Last Updated: 18 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

To examine the efficacy and safety of venlafaxine XR in the treatment of physical and emotional symptoms in patients with an operationally-defined diagnosis of multisomatoform disorder (MSD).

Detailed Description

The purpose of this study is to examine the efficacy and safety of venlafaxine XR in the treatment of physical and emotional symptoms in patients with an operationally-defined diagnosis of MSD. Primary efficacy will be evaluated using the PHQ-15 scale, and secondary efficacy will be evaluated using the HAM-D17, HAM-A, CGI, MQOL-PS, VAS and SF-36 evaluation scales. Assessment scales and questionnaires will be administered at specified clinical visits between screening and Week 12 (or discontinuation).

Registry

clinicaltrials.gov

Start Date

August 2004

End Date

June 2006

Last Updated

18 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

•· Subjects must be at least 18 years of age and meet DSM-IV diagnostic criteria for major depressive disorder, generalized anxiety disorder, and/ or social anxiety disorder, meet clinical criteria for MSD, have a total score of greater than or equal to 14 on the HAM-D17 or a total score of greater than or equal to 12 on the HAM-A at screening and no more than a 25% decrease in total HAM-D17 score or total HAM-A score from screening to randomization.

Exclusion Criteria

•a history of an inability to tolerate or failure to respond to greater than or equal to 2 antidepressants of sufficient dose and duration of administration for the treatment of symptoms present in the current illness;
•a current or past history of mania, bipolar disorder, schizophrenia, or other psychotic disorder;
•history of seizure disorder other than childhood febrile seizure;
•presence of a serious or clinically unstable medical illness or psychiatric condition that would compromise the participation in the study;
•previous intolerance or hypersensitivity to venlafaxine or venlafaxine XR or nonresponse to a previous adequate trial of any of these drugs, or use of any nonpsychopharmacologic drug with psychotropic effects within 7 days of study randomization;
•Use of MAOI or fluoxetine within 30 days of screening; or
•Use of ECT within 3 months of screening.

Outcomes

Primary Outcomes

The primary endpoint is the change from baseline to Week 12 in the PHQ-15 total score.

Secondary Outcomes

Efficacy will be evaluated by changes in the total scores of the HAM-D17, HAM-A, CGI, MQOL-PS, VAS and SF-36. Safety will be monitored by collecting spontaneously reported adverse events; vital signs and laboratory measures according to the Schedule.